[1] |
Mejia-Vilet JM, Malvar A, Arazi A, et al. The lupus nephritis management renaissance[J]. Kidney Int, 2022, 101(2): 242-255.
doi: 10.1016/j.kint.2021.09.012
|
[2] |
张爱华, 朱春华. 儿童狼疮性肾炎诊治现状及面临的困难[J]. 中华儿科杂志, 2021, 59(9): 717-719.
|
[3] |
Montigny PM, Houssiau FA. New treatment options in lupus nephritis[J]. Arch Immunol Ther Exp (Warsz), 2022, 70(1): 11.
doi: 10.1007/s00005-022-00647-8
|
[4] |
中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2018, 56(2): 88-94.
|
[5] |
Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions[J]. Kidney Int, 2013, 83(4): 715-723.
doi: 10.1038/ki.2012.409
|
[6] |
Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient[J]. Kidney Int, 2012, 82(8): 840-856.
doi: 10.1038/ki.2012.280
pmid: 22895519
|
[7] |
孙莉, 徐虹, 刘海梅, 等. 上海单中心101例儿童狼疮性肾炎的长期随访分析[J]. 中华儿科杂志, 2011, 49(11): 820-824.
|
[8] |
Gallan AJ, Chang A. A new paradigm for renal thrombotic microangiopathy[J]. Semin Diagn Pathol, 2020, 37(3): 121-126.
doi: S0740-2570(20)30008-3
pmid: 32085935
|
[9] |
Gomes RC, Silva MF, Kozu K, et al. Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis: a Brazilian multicenter study[J]. Arthritis Care Res (Hoboken), 2016, 68(11): 1736-1741.
doi: 10.1002/acr.22881
pmid: 27014968
|
[10] |
Couture J, Silverman ED. Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus[J]. Curr Opin Rheumatol, 2016, 28(5): 488-496.
doi: 10.1097/BOR.0000000000000317
pmid: 27341622
|
[11] |
Ameer MA, Chaudhry H, Mushtaq J, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management[J]. Cureus, 2022, 14(10): e30330.
|
[12] |
Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020[J]. Am J Kidney Dis, 2020, 76(2): 265-281.
doi: S0272-6386(19)31170-9
pmid: 32220510
|
[13] |
Strufaldi FL, Menezes Neves PDMM, Dias CB, et al. Renal thrombotic microangiopathy associated to worse renal prognosis in lupus nephritis[J]. J Nephrol, 2021, 34(4): 1147-1156.
doi: 10.1007/s40620-020-00938-3
pmid: 33570723
|
[14] |
Pinheiro SVB, Dias RF, Fabiano RCG, et al. Pediatric lupus nephritis[J]. J Bras Nefrol, 2019, 41(2): 252-265.
doi: S0101-28002019000200252
pmid: 30465590
|
[15] |
Onuora S. LLDAS is an attainable SLE treatment target[J]. Nat Rev Rheumatol, 2019, 15(11): 636.
doi: 10.1038/s41584-019-0312-9
pmid: 31548697
|
[16] |
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76(3): 554-561.
doi: 10.1136/annrheumdis-2016-209519
pmid: 27884822
|
[17] |
Massicotte-Azarniouch D, Kotzen E, Todd S, et al. Kidney thrombotic microangiopathy in lupus nephritis: impact on treatment and prognosis[J]. Lupus, 2022, 31(10): 1175-1185.
doi: 10.1177/09612033221106301
pmid: 35650019
|
[18] |
Almaani S, Parikh SV. Membranous lupus nephritis: a clinical review[J]. Adv Chronic Kidney Dis, 2019, 26(5): 393-403.
doi: 10.1053/j.ackd.2019.08.009
|
[19] |
Chen X, Cheng W, Wang G, et al. Clinical characteristics and prognosis of renal thrombotic microangiopathy in lupus nephritis[J]. Iran J Kidney Dis, 2021, 15(3): 169-176.
pmid: 33994376
|
[20] |
Massicotte-Azarniouch D, Kotzen E, Todd S, et al. Kidney thrombotic microangiopathy in lupus nephritis: impact on treatment and prognosis[J]. Lupus, 2022, 31(10): 1175-1185.
doi: 10.1177/09612033221106301
pmid: 35650019
|
[21] |
Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis[J]. Pediatr Nephrol, 2021, 36(6): 1377-1385.
doi: 10.1007/s00467-020-04686-1
|